Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia

Gastroenterology

Volumn 151, Issue 3, 2016, Pages 427-439.e6

  Ladabaum, Uri ^a   Mannalithara, Ajitha ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adherence; Colon Cancer; Early Detection; Prevention

Indexed keywords

DNA;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; COLONOSCOPY; COLORECTAL CANCER; COLORECTAL POLYP; COLORECTAL TUMOR; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DNA SCREENING; FECES ANALYSIS; HEALTH CARE COST; HUMAN; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; MONTE CARLO METHOD; MULTITARGET STOOL DNA TEST; PATIENT PARTICIPATION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; CHEMISTRY; COLORECTAL NEOPLASMS; COST BENEFIT ANALYSIS; EARLY CANCER DIAGNOSIS; ECONOMICS; FECES; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; PROCEDURES; UNITED STATES;

AGED; COLONOSCOPY; COLORECTAL NEOPLASMS; COMPARATIVE EFFECTIVENESS RESEARCH; COST-BENEFIT ANALYSIS; DNA, NEOPLASM; EARLY DETECTION OF CANCER; FECES; HUMANS; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES;

EID: 84995487591     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2016.06.003     Document Type: Article

References (82)

1. 1 Hewitson, P., Glasziou, P., Watson, E., et al. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 103 (2008), 1541–1549.
2. 2 Elmunzer, B.J., Hayward, R.A., Schoenfeld, P.S., et al. Effect of flexible sigmoidoscopy-based screening on incidence and mortality of colorectal cancer: a systematic review and meta-analysis of randomized controlled trials. PLoS Med, 9, 2012, e1001352.
3. 3 Rabeneck, L., Rumble, R.B., Thompson, F., et al. Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening. Can J Gastroenterol 26 (2012), 131–147.
4. 4 Lee, J.K., Liles, E.G., Bent, S., et al. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med, 160, 2014, 171.
5. 5 Rossi, P.G., Vicentini, M., Sacchettini, C., et al. Impact of screening program on incidence of colorectal cancer: a cohort study in Italy. Am J Gastroenterol 110 (2015), 1359–1366.
6. 6 Jensen, C.D., Corley, D.A., Quinn, V.P., et al. Fecal immunochemical test program performance over 4 rounds of annual screening: a retrospective cohort study. Ann Intern Med 164 (2016), 456–463.
7. 7 Baxter, N.N., Warren, J.L., Barrett, M.J., et al. Association between colonoscopy and colorectal cancer mortality in a US cohort according to site of cancer and colonoscopist specialty. J Clin Oncol 30 (2012), 2664–2669.
8. 8 Brenner, H., Chang-Claude, J., Seiler, C.M., et al. Protection from colorectal cancer after colonoscopy: a population-based, case-control study. Ann Intern Med 154 (2011), 22–30.
9. 9 Nishihara, R., Wu, K., Lochhead, P., et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 369 (2013), 1095–1105.
10. 10 Zauber, A.G., Winawer, S.J., O'Brien, M.J., et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 366 (2012), 687–696.
11. 11 Imperiale, T.F., Ransohoff, D.F., Itzkowitz, S.H., et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 370 (2014), 1287–1297.
12. 12 Duncan, A., Turnbull, D., Wilson, C., et al. Behavioural and demographic predictors of adherence to three consecutive faecal occult blood test screening opportunities: a population study. BMC Public Health, 14, 2014, 238.
13. 13 Lo, S.H., Halloran, S., Snowball, J., et al. Colorectal cancer screening uptake over three biennial invitation rounds in the English bowel cancer screening programme. Gut 64 (2015), 282–291.
14. 14 Subramanian, S., Tangka, F.K., Hoover, S., et al. Costs of planning and implementing the CDC's Colorectal Cancer Screening Demonstration Program. Cancer 119:Suppl 15 (2013), 2855–2862.
15. 15 Subramanian, S., Tangka, F.K., Hoover, S., et al. Clinical and programmatic costs of implementing colorectal cancer screening: evaluation of five programs. Eval Program Plann 34 (2011), 147–153.
16. 16 Crotta, S., Segnan, N., Paganin, S., et al. High rate of advanced adenoma detection in 4 rounds of colorectal cancer screening with the fecal immunochemical test. Clin Gastroenterol Hepatol 10 (2012), 633–638.
17. 17 Kapidzic, A., Grobbee, E.J., Hol, L., et al. Attendance and yield over three rounds of population-based fecal immunochemical test screening. Am J Gastroenterol 109 (2014), 1257–1264.
18. 18 Ladabaum, U., Levin, Z., Mannalithara, A., et al. Colorectal testing utilization and payments in a large cohort of commercially insured US adults. Am J Gastroenterol 109 (2014), 1513–1525.
19. 19 Ladabaum, U., Song, K., Projected national impact of colorectal cancer screening on clinical and economic outcomes and health services demand. Gastroenterology 129 (2005), 1151–1162.
20. 20 Sharaf, R.N., Ladabaum, U., Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies. Am J Gastroenterol 108 (2013), 120–132.
21. 21 Mandel, J.S., Bond, J.H., Church, T.R., et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 328 (1993), 1365–1371.
22. 22 Mandel, J.S., Church, T.R., Bond, J.H., et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 343 (2000), 1603–1607.
23. 23 Atkin, W.S., Edwards, R., Kralj-Hans, I., et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 375 (2010), 1624–1633.
24. 24 Segnan, N., Armaroli, P., Bonelli, L., et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial–SCORE. J Natl Cancer Inst 103 (2011), 1310–1322.
25. 25 Schoen, R.E., Pinsky, P.F., Weissfeld, J.L., et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 366 (2012), 2345–2357.
26. 26 Ladabaum, U., Allen, J., Wandell, M., et al. Colorectal cancer screening with blood-based biomarkers: cost-effectiveness of methylated septin 9 DNA vs. current strategies. Cancer Epidemiol Biomarkers Prev 22 (2013), 1567–1576.
27. 27 Wong, M.C.S., Ching, J.Y.L., Lam, T.Y.T., et al. Prospective cohort study of compliance with faecal immunochemical tests for colorectal cancer screening in Hong Kong. Prev Med 57 (2013), 227–231.
28. 28 Liang, P.S., Wheat, C.L., Abhat, A., et al. Adherence to competing strategies for colorectal cancer screening over 3 years. Am J Gastroenterol 111 (2016), 105–114.
29. 29 Hardcastle, J.D., Armitage, N.C., Chamberlain, J., et al. Fecal occult blood screening for colorectal cancer in the general population. Results of a controlled trial. Cancer 58 (1986), 397–403.
30. 30 Hardcastle, J.D., Chamberlain, J.O., Robinson, M.H., et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348 (1996), 1472–1477.
31. 31 Kewenter, J., Brevinge, H., Engaras, B., et al. Results of screening, rescreening, and follow-up in a prospective randomized study for detection of colorectal cancer by fecal occult blood testing. Results for 68,308 subjects. Scand J Gastroenterol 29 (1994), 468–473.
32. 32 Lindholm, E., Brevinge, H., Haglind, E., Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. Br J Surg 95 (2008), 1029–1036.
33. 33 Centers for Medicare and Medicaid Services. Clinical laboratory fee schedule 2015. Available from: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/. Accessed: February 19, 2016.
34. 34 Centers for Medicare and Medicaid Services. Inpatient prospective payment system 2015. Available from: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/. Accessed: February 19, 2016.
35. 35 Centers for Medicare and Medicaid Services. Physician fee schedule 2015. Available from: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/. Accessed: February 19, 2016.
36. 36 Zauber AG, Lansdorp-Vogelaar I, Wilschut J, et al. Technology assessment: cost-effectiveness of DNA stool testing to screen for colorectal cancer. Report to AHRQ and CMS from the Cancer Intervention and Surveillance Modeling Network (CISNET) for MISCAN and SimCRC Models 2007. Available from: https://www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/id52TA.pdf. Accessed July 28, 2016.
37. 37 How much does Cologuard cost? Available from: http://www.cologuardtest.com/what-to-expect-with-cologuard/faq/cologuard-cost-how-much-is-cologuard. Accessed: February 12, 2016.
38. 38 Siegel, J.E., Weinstein, M.C., Russell, L.B., et al. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 276 (1996), 1339–1341.
39. 39 Weinstein, M.C., Siegel, J.E., Gold, M.R., et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 276 (1996), 1253–1258.
40. 40 Lipscomb, J., Weinstein, M.C., Torrance, G.W., Time preference. Gold, M.R., Siegel, J.E., Russell, L.B., et al. (eds.) Cost-effectiveness in health and medicine, 1996, Oxford University Press, New York, 214–235.
41. 41 Briggs, A., Claxton, K., Sculpher, M., Making decision models probabilistic. Decision modelling for health economic evaluation. 2006, Oxford University Press, Cambridge, MA, 77–120.
42. 42 Quintero, E., Castells, A., Bujanda, L., et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 366 (2012), 697–706.
43. 43 Chen, L.A., Santos, S., Jandorf, L., et al. A program to enhance completion of screening colonoscopy among urban minorities. Clin Gastroenterol Hepatol 6 (2008), 443–450.
44. 44 Jandorf, L., Braschi, C., Ernstoff, E., et al. Culturally targeted patient navigation for increasing African Americans' adherence to screening colonoscopy: a randomized clinical trial. Cancer Epidemiol Biomarkers Prev 22 (2013), 1577–1587.
45. 45 Elkin, E.B., Shapiro, E., Snow, J.G., et al. The economic impact of a patient navigator program to increase screening colonoscopy. Cancer 118 (2012), 5982–5988.
46. 46 Ladabaum, U., Mannalithara, A., Jandorf, L., et al. Cost-effectiveness of patient navigation to increase adherence with screening colonoscopy among minority individuals. Cancer 121 (2015), 1088–1097.
47. 47 Zauber A, Knudsen A, Rutter CM, et al. Evaluating the Benefits and Harms of Colorectal Cancer Screening Strategies: A Collaborative Modeling Approach. Rockville, MD: Agency for Healthcare Research and Quality; 2015. AHRQ publication 14-05203-EF-2.
48. 48 Vatn, M.H., Stalsberg, H., The prevalence of polyps of the large intestine in Oslo: an autopsy study. Cancer 49 (1982), 819–825.
49. 49 Williams, A.R., Balasooriya, B.A., Day, D.W., Polyps and cancer of the large bowel: a necropsy study in Liverpool. Gut 23 (1982), 835–842.
50. 50 Clark, J.C., Collan, Y., Eide, T.J., et al. Prevalence of polyps in an autopsy series from areas with varying incidence of large-bowel cancer. Int J Cancer 36 (1985), 179–186.
51. 51 Arminski, T.C., McLean, M.D., Incidence and distribution of adenomatous polyps of the colon and rectum based on 1,000 autopsy examinations. Dis Colon Rectum 7 (1964), 249–261.
52. 52 Rickert, R.R., Auerbach, O., Garfinkel, L., et al. Adenomatous lesions of the large bowel: an autopsy survey. Cancer 43 (1979), 1847–1857.
53. 53 Wagner, J.L., Tunis, S., Brown, M., et al. Cost-effectiveness of colorectal cancer screening in average risk adults. Young, G., Rozen, P., Levin, B., (eds.) Prevention and early detection of colorectal cancer, 1996, WB Saunders, Philadelphia, 321–356.
54. 54 Ries, L.A.G., Kosary, C.L., Hankey, B.F., et al. SEER cancer statistics review, 1973-1994. NIH publication 97-2789. 1997, National Cancer Institute, Bethesda, MD, 17–166.
55. 55 Bernold, D.M., Sinicrope, F.A., Advances in chemotherapy for colorectal cancer. Clin Gastroenterol Hepatol 4 (2006), 808–821.
56. 56 Cunningham, D., Humblet, Y., Siena, S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004), 337–345.
57. 57 Goldberg, R.M., Sargent, D.J., Morton, R.F., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22 (2004), 23–30.
58. 58 Hurwitz, H., Fehrenbacher, L., Novotny, W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004), 2335–2342.
59. 59 Kabbinavar, F., Hurwitz, H.I., Fehrenbacher, L., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21 (2003), 60–65.
60. 60 Meyerhardt, J.A., Mayer, R.J., Systemic therapy for colorectal cancer. N Engl J Med 352 (2005), 476–487.
61. 61 Saltz, L.B., Meropol, N.J., Loehrer, P.J. Sr., et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22 (2004), 1201–1208.
62. 62 Winawer, S.J., Fletcher, R.H., Miller, L., et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 112 (1997), 594–642.
63. 63 van Rijn, J.C., Reitsma, J.B., Stoker, J., et al. Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol 101 (2006), 343–350.
64. 64 Pickhardt, P.J., Choi, J.R., Hwang, I., et al. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med 349 (2003), 2191–2200.
65. 65 Lin JS, Piper MA, Perdue LA, et al. Screening for Colorectal Cancer: A Systematic Review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 135. AHRQ Publication No. 14-05203-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2016.
66. 66 Rabeneck, L., Paszat, L.F., Hilsden, R.J., et al. Bleeding and perforation after outpatient colonoscopy and their risk factors in usual clinical practice. Gastroenterology 135 (2008), 1899–1906 1906 e1.
67. 67 Gatto, N.M., Frucht, H., Sundararajan, V., et al. Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study. J Natl Cancer Inst 95 (2003), 230–236.
68. 68 Anderson, M.L., Pasha, T.M., Leighton, J.A., Endoscopic perforation of the colon: lessons from a 10-year study. Am J Gastroenterol 95 (2000), 3418–3422.
69. 69 Ramsey, S.D., Andersen, M.R., Etzioni, R., et al. Quality of life in survivors of colorectal carcinoma. Cancer 88 (2000), 1294–1303.
70. 1 Ladabaum, U., Chopra, C.L., Huang, G., et al. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis. Ann Intern Med 135 (2001), 769–781.
71. 2 Ladabaum, U., Phillips, K.A., Colorectal cancer screening: differential costs for younger versus older Americans. Am J Prev Med 30 (2006), 378–384.
72. 3 Ladabaum, U., Song, K., Projected national impact of colorectal cancer screening on clinical and economic outcomes and health services demand. Gastroenterology 129 (2005), 1151–1162.
73. 4 Ladabaum, U., Song, K., Fendrick, A.M., Colorectal neoplasia screening with virtual colonoscopy: when, at what cost, and with what national impact?. Clin Gastroenterol Hepatol 2 (2004), 554–563.
74. 5 Song, K., Fendrick, A.M., Ladabaum, U., Fecal DNA testing compared to conventional colorectal cancer screening methods: a decision analysis. Gastroenterology 126 (2004), 1270–1279.
75. 6 Parekh, M., Fendrick, A.M., Ladabaum, U., As tests evolve and costs of cancer care rise: reappraising stool-based screening for colorectal neoplasia. Aliment Pharmacol Ther 27 (2008), 697–712.
76. 7 Arias, E., United States life tables, 2008. National vital statistics reports. Vol 61. 2012, National Center for Health Statistics, Hyattsville, MD Available from: http://www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61_03.pdf Accessed: March 28, 2014.
77. 8 Mandel, J.S., Bond, J.H., Church, T.R., et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 328 (1993), 1365–1371.
78. 9 Mandel, J.S., Church, T.R., Bond, J.H., et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 343 (2000), 1603–1607.
79. 10 Sharaf, R.N., Ladabaum, U., Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies. Am J Gastroenterol 108 (2013), 120–132.
80. 11 Atkin, W.S., Edwards, R., Kralj-Hans, I., et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 375 (2010), 1624–1633.
81. 12 Segnan, N., Armaroli, P., Bonelli, L., et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial–SCORE. J Natl Cancer Inst 103 (2011), 1310–1322.
82. 13 Schoen, R.E., Pinsky, P.F., Weissfeld, J.L., et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 366 (2012), 2345–2357.